The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes

Patients starting semaglutide after other anti-obesity medications lost 14.3% of their body weight at 12 months, compared to 10.6% in those who had never taken such medications.

• A total of 305 patients were analyzed for weight loss outcomes after starting semaglutide.
• AOM-naïve patients (n = 231) experienced greater weight loss at 3, 6, 9, and 12 months compared to non-AOM-naïve patients (n = 74).
• At 12 months, 48% of AOM-naïve patients achieved at least 15% total body weight loss (TBWL), compared to 21% of non-AOM-naïve patients.
• The proportion of patients achieving at least 20% TBWL at 12 months was 27% in the AOM-naïve group versus 4% in the non-AOM-naïve group.
• Statistical significance was found with p < 0.0001 for weight loss at 3, 6, and 9 months, and p = 0.01 at 12 months.

AI simplified